Olanzapine is an atypical antipsychotic prescribed for schizophrenia, bipolar disorder, and, in combination with fluoxetine, treatment resistant depression. People taking it sometimes worry a pre employment or workplace drug screen will flag it, or that it will show up as something it is not. This post explains what olanzapine actually is, whether any standard panel is built to detect it, what the published cross reactivity record shows for olanzapine compared with a closely related antipsychotic that does have documented reports, how lab confirmation resolves a presumptive result, and how the Medical Review Officer process handles a disputed screen.
What olanzapine is and how it is classified
Olanzapine is a thienobenzodiazepine class atypical antipsychotic sold under its generic name and under brand names, used alone or combined with fluoxetine. The current prescribing information, submitted to the National Library of Medicine and published on DailyMed, describes it strictly as an antipsychotic agent with no abuse warning and no controlled substance designation. The Drug Enforcement Administration publishes the current controlled substance schedules through its Office of Diversion Control scheduling page, and the schedules themselves are codified at 21 CFR Part 1308. Olanzapine does not appear on any DEA schedule. It is prescription only but not a controlled substance, which is the starting point for why standard drug panels are not built around it.
Background on the drug's pharmacology and clinical use is also summarized in the National Library of Medicine's StatPearls chapter on olanzapine, a peer reviewed clinical reference hosted on NIH Bookshelf.
What standard panels are built to detect
A standard 5 panel urine screen targets amphetamines, cocaine metabolite, marijuana metabolite (THC), opiates, and phencyclidine (PCP). Expanded 10 and 12 panel configurations add classes such as barbiturates, benzodiazepines, methadone, methaqualone, propoxyphene, and in some product lines additional synthetic opioids. The federal mandatory guidelines that define these analyte groups and their cutoffs for federally regulated testing are published through the Federal Register mandatory guidelines for federal workplace drug testing programs. Antipsychotics as a drug class, olanzapine included, are not one of the analyte groups any of these immunoassay panels are designed to bind. The antibodies used in rapid cups and dip cards are built around the chemical structure of amphetamines, opioids, benzodiazepines, cannabinoid metabolites, and the other named classes, not thienobenzodiazepine antipsychotics.
Olanzapine versus quetiapine: why the published evidence differs
This is the part that causes real confusion, because olanzapine gets grouped with other atypical antipsychotics in casual conversation, and one of those relatives, quetiapine, does have a documented interference problem. A case report published in PubMed Central describes a patient on quetiapine whose urine immunoassay screen returned a false positive result, consistent with earlier literature describing quetiapine's structural similarity to tricyclic antidepressant and methadone immunoassay targets. Our separate post on Seroquel and quetiapine false positives covers that evidence in detail.
Olanzapine's chemical structure is different enough from quetiapine's that the two should not be assumed to behave the same way on an immunoassay. A search of the National Library of Medicine's PubMed Central database for olanzapine specific cross reactivity case reports or validation studies, run while researching this article, did not return a published report describing olanzapine triggering a false positive on any standard immunoassay drug class. That is the honest, current state of the literature, not a guarantee that no result involving olanzapine could ever be questioned. The table below lines up several atypical antipsychotics against what has actually been published.
Atypical antipsychotics and published immunoassay cross reactivity
| Medication | Drug class | Controlled substance | Published cross reactivity |
|---|---|---|---|
| Olanzapine | Thienobenzodiazepine | No | No published cross reactivity reports identified |
| Quetiapine | Dibenzothiazepine | No | Published case reports of tricyclic antidepressant and methadone screen false positives |
| Aripiprazole | Quinolinone derivative | No | Published reports linked to amphetamine class false positives, see our dedicated post below |
| Risperidone | Benzisoxazole derivative | No | No published cross reactivity reports identified |
| Clozapine | Dibenzodiazepine | No | No published cross reactivity reports identified |
Aripiprazole is the other antipsychotic in this group with an actual published signal, which we cover in our post on Abilify and amphetamine false positive screens. Olanzapine does not carry a comparable published report, and the difference matters because it means a laboratory or MRO reviewing an olanzapine prescription against a non negative screen is not working from an established cross reactivity pattern the way they might with quetiapine or aripiprazole.
Screening versus confirmation
A cup or dip card immunoassay is a presumptive screen, not a final result. It is designed for speed and sensitivity, which means it can occasionally flag a specimen that does not contain the target drug the panel is looking for. When a screen comes back non negative, the correct next step under federally regulated testing, and the practice responsible employers follow for non regulated testing too, is confirmation by gas chromatography mass spectrometry (GC/MS) or liquid chromatography tandem mass spectrometry (LC/MS/MS). Confirmation identifies the exact molecule present rather than relying on antibody binding, which is why it is far more specific than a screen. Because olanzapine is not a chemical match for amphetamines, opiates, benzodiazepines, tricyclic antidepressants, or any other standard panel analyte, confirmation testing would not identify it as the cause of a non negative result on those classes even in the rare case where a screen flagged a specimen for an unrelated reason.
MRO review and prescription documentation
For DOT regulated tests and many non regulated employment programs, a non negative screen does not become a reportable positive until it passes through review by a Medical Review Officer. The MRO is a licensed physician trained to interpret laboratory results and to contact the individual confidentially about any legitimate medical explanation, including current prescriptions. The verification process, the documentation an MRO can request, and the timelines involved are set out in 49 CFR Part 40, the federal regulation governing MRO review of drug and alcohol test results. Someone taking olanzapine who is contacted by an MRO about a result should be ready to provide prescription information and pharmacy records on request. Because standard panels are not built to detect antipsychotics as a class, there is ordinarily nothing in an olanzapine prescription for an MRO to reconcile against a non negative amphetamine, opiate, or benzodiazepine screen, but documentation is still the right response whenever a question comes up.
What employers should do with a disputed result
If an employee reports taking olanzapine, quetiapine, or any other prescribed antipsychotic and a result is still in question, the employer's role is procedural, not diagnostic. Route the specimen and the question to the certified laboratory and the MRO rather than making a determination in house. Keep chain of custody documentation intact, give the employee the opportunity the MRO process provides to explain a prescription, and rely on confirmation testing rather than the initial screen for any adverse decision. Employers should consult their own legal counsel on how to apply these steps within a written testing policy, since documentation practices and state level rules affecting workplace testing can vary.
It is also worth separating two different questions that tend to get merged in conversation. The first is whether a medication could cause a false positive screen on a drug class it is not related to, which for olanzapine has no published basis at this time. The second is whether a panel is built to detect the medication itself as a target analyte, meaning the test is looking for it on purpose. Olanzapine fails that second test too, because no standard SAMHSA referenced or DOT panel configuration includes antipsychotics as a target class. Employers and employees asking about a specific device should confirm with the laboratory which analytes that device actually covers rather than assuming based on a drug's general category.
Frequently asked questions
Does olanzapine show up as a false positive on a standard drug test panel?
No published cross reactivity report identifies olanzapine as a cause of a false positive on standard amphetamine, opiate, benzodiazepine, THC, PCP, or tricyclic antidepressant immunoassay screens, based on a search of the National Library of Medicine's biomedical literature.
Is olanzapine a controlled substance?
No. Olanzapine does not appear on any DEA schedule under 21 CFR Part 1308. It is a prescription medication but not a controlled substance, according to the current DailyMed prescribing information.
Is olanzapine the same as quetiapine for drug testing purposes?
No. They are both atypical antipsychotics but structurally different drugs. Quetiapine has published case reports of tricyclic antidepressant and methadone immunoassay false positives, documented in a report in PubMed Central. Olanzapine does not have a comparable published report.
Will a lab confirmation test detect olanzapine as an illegal drug?
No. GC/MS and LC/MS confirmation identify the exact molecule present in a specimen. Olanzapine is not chemically related to any standard panel analyte, so confirmation testing would not identify it as one.
What should someone taking olanzapine do before a workplace drug test?
Bring current prescription information in case the Medical Review Officer has questions about a result, and answer the MRO's confidential call if one is placed. There is no dosing or medical action needed specific to drug testing, and this is not medical advice.
What should an employer do if an employee says an antipsychotic medication affected their result?
Send the question to the certified laboratory and the MRO under the standard verification process set out in 49 CFR Part 40 rather than deciding in house, and keep chain of custody documentation complete.
Employers that want to standardize how non negative screens are handled can review our drug test cup collection for panel configurations that match a written testing policy.
This article is general information about drug testing science and procedure, not medical or legal advice. Anyone with questions about a specific medication or test result should talk to a licensed physician, their Medical Review Officer, or qualified legal counsel.
